Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial

Authors

Institutions

Publication Details

Journal
Circulation Cardiovascular Interventions
Published
2025-04-23
DOI
https://doi.org/10.1161/circinterventions.124.014961
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial

Christian Hassager, Jesper Kjærgaard, Lars Køber, Hanne Berg Ravn et al.
Circulation Cardiovascular Interventions
Diabetes Treatment and Management
article

Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial

Christian Hassager, Jesper Kjærgaard, Lars Køber, Hanne Berg Ravn, Sebastian C. Wiberg, Peter Skov Olsen, Hasse Møller‐Sørensen, Dan Eik Høfsten, Jesper Ravn, Jens Christian Nilsson, Astrid Duus Mikkelsen, Christian H. Møller, Søren Boesgaard
article en

Abstract

No abstract available for this paper.
Circulation Cardiovascular InterventionsVol. 18(5)
University of Copenhagen (DK), Odense University Hospital (DK), Copenhagen University Hospital (DK), Rigshospitalet (DK), University College Copenhagen (DK)
Good health and well-being
Openalex Percentile: Top 89%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.